Overall I thought the call was excellent. The one question I have is it was mentioned that CTIX narrowly missed getting a grant/funding for the K PH2 trial for Pancreatic Cancer trial (at Mayo?). It sounds like having an oral version of K would have secured moving forward. Does anyone know if this is a lost opportunity or if/when CTIX has an oral version of K that a PH2 would/could be started? Bashers may get their way short term but the science will eventually nail their ass. The stock is currently down 11 cents but only 59k shares traded tells me that anyone who has been here for any length of time knows what they own and are long and strong.